Kortepeter CM[au] - Search Results

Year	Number of Results
2005	1
2008	1
2017	2
2018	2
2019	3
2020	5
2021	3
2022	0

1

Expanding spectrum of opportunistic infections associated with dimethyl fumarate.

Kim T, Croteau D, Brinker A, Jones DE, Lee PR, Kortepeter CM. Kim T, et al. Among authors: kortepeter cm. Mult Scler. 2021 Jul;27(8):1301-1305. doi: 10.1177/1352458520977132. Epub 2020 Dec 10. Mult Scler. 2021. PMID: 33300850

2

Reporting Adverse Events for Cannabis to the FDA.

Hines MC, Harinstein LM, Kortepeter CM. Hines MC, et al. Among authors: kortepeter cm. N Engl J Med. 2020 Jan 2;382(1):98. doi: 10.1056/NEJMc1913460. N Engl J Med. 2020. PMID: 31875515 No abstract available.

3

Tumefactive multiple sclerosis in association with fingolimod initiation and discontinuation.

Croteau D, Tobenkin A, Brinker A, Kortepeter CM. Croteau D, et al. Among authors: kortepeter cm. Mult Scler. 2021 May;27(6):903-912. doi: 10.1177/1352458520938354. Epub 2020 Jul 14. Mult Scler. 2021. PMID: 32662718

4

Hemophagocytic lymphohistiocytosis associated with the use of lamotrigine.

Kim T, Kulick CG, Kortepeter CM, Brinker A, Waldron P. Kim T, et al. Among authors: kortepeter cm. Neurology. 2019 May 21;92(21):e2401-e2405. doi: 10.1212/WNL.0000000000007517. Epub 2019 Apr 17. Neurology. 2019. PMID: 30996059

5

Leveraging Case Narratives to Enhance Patient Age Ascertainment from Adverse Event Reports.

Pham P, Cheng C, Wu E, Kim I, Zhang R, Ma Y, Kortepeter CM, Muñoz MA. Pham P, et al. Among authors: kortepeter cm. Pharmaceut Med. 2021 Sep;35(5):307-316. doi: 10.1007/s40290-021-00398-5. Epub 2021 Sep 2. Pharmaceut Med. 2021. PMID: 34476768 Free PMC article.

6

Acute acalculous cholecystitis: A new safety risk for patients with MS treated with alemtuzumab.

Croteau D, Flowers C, Kulick CG, Brinker A, Kortepeter CM. Croteau D, et al. Among authors: kortepeter cm. Neurology. 2018 May 1;90(18):e1548-e1552. doi: 10.1212/WNL.0000000000005422. Epub 2018 Mar 30. Neurology. 2018. PMID: 29602912 Review.

7

Towards Automating Adverse Event Review: A Prediction Model for Case Report Utility.

Muñoz MA, Dal Pan GJ, Wei YJ, Delcher C, Xiao H, Kortepeter CM, Winterstein AG. Muñoz MA, et al. Among authors: kortepeter cm. Drug Saf. 2020 Apr;43(4):329-338. doi: 10.1007/s40264-019-00897-0. Drug Saf. 2020. PMID: 31912439

8

Liver injury associated with dimethyl fumarate in multiple sclerosis patients.

Muñoz MA, Kulick CG, Kortepeter CM, Levin RL, Avigan MI. Muñoz MA, et al. Among authors: kortepeter cm. Mult Scler. 2017 Dec;23(14):1947-1949. doi: 10.1177/1352458516688351. Epub 2017 Jan 13. Mult Scler. 2017. PMID: 28086032

9

Evaluation of Postmarketing Reports from Industry-Sponsored Programs in Drug Safety Surveillance.

Harinstein L, Kalra D, Kortepeter CM, Muñoz MA, Wu E, Dal Pan GJ. Harinstein L, et al. Among authors: kortepeter cm. Drug Saf. 2019 May;42(5):649-655. doi: 10.1007/s40264-018-0759-7. Drug Saf. 2019. PMID: 30569267

10

An Evaluation of Postmarketing Reports with an Outcome of Death in the US FDA Adverse Event Reporting System.

Marwitz K, Jones SC, Kortepeter CM, Dal Pan GJ, Muñoz MA. Marwitz K, et al. Among authors: kortepeter cm. Drug Saf. 2020 May;43(5):457-465. doi: 10.1007/s40264-020-00908-5. Drug Saf. 2020. PMID: 31981082

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results